Trial · NCT02906020
Adverse events2,912
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 2,912
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Tinnitus | Ear and labyrinth disorders | Part 1: Placebo (ROW) | 0 | 4 | 0 |
| other | Tinnitus | Ear and labyrinth disorders | Part 1: Venglustat 4 mg (ROW) | 0 | 4 | 0 |
| other | Tinnitus | Ear and labyrinth disorders | Part 1: Venglustat 8 mg (ROW) | 0 | 5 | 0 |
| other | Tinnitus | Ear and labyrinth disorders | Part 1: Venglustat 15 mg (ROW) | 0 | 4 | 0 |
| other | Tinnitus | Ear and labyrinth disorders | Part 1: Placebo (Japan Only) | 0 | 3 | 0 |
| other | Tinnitus | Ear and labyrinth disorders | Part 1: Venglustat 4 mg (Japan Only) | 0 | 3 | 0 |
| other | Tinnitus | Ear and labyrinth disorders | Part 1: Venglustat 8 mg (Japan Only) | 0 | 3 | 0 |
| other | Tinnitus | Ear and labyrinth disorders | Part 1: Venglustat 15 mg (Japan Only) | 0 | 3 | 0 |
| other | Tinnitus | Ear and labyrinth disorders | Part 2, DB Period: Placebo | 1 | 111 | 1 |
| other | Tinnitus | Ear and labyrinth disorders | Part 2, DB Period: Venglustat 15 mg | 0 | 110 | 0 |
| other | Tinnitus | Ear and labyrinth disorders | Part 2, DB Period: Placebo (Re-randomized From Part 1) | 0 | 10 | 0 |
| other | Tinnitus | Ear and labyrinth disorders | Part 2, DB Period: Venglustat 15 mg (Re-randomized From Part 1) | 0 | 13 | 0 |
| other | Tinnitus | Ear and labyrinth disorders | Part 2, LTFU Period: Placebo Then Venglustat 15 mg | 0 | 87 | 0 |
| other | Tinnitus | Ear and labyrinth disorders | Part 2, LTFU Period: Venglustat 15 mg | 0 | 75 | 0 |
| other | Tinnitus | Ear and labyrinth disorders | Part 2, LTFU: Placebo Then Veng 15 mg (Re-randomized From Part 1) | 1 | 10 | 1 |
| other | Tinnitus | Ear and labyrinth disorders | Part 2, LTFU: Venglustat 15 mg (Re-randomized From Part 1) | 0 | 11 | 0 |
| other | Tympanic Membrane Perforation | Ear and labyrinth disorders | Part 1: Placebo (ROW) | 0 | 4 | 0 |
| other | Tympanic Membrane Perforation | Ear and labyrinth disorders | Part 1: Venglustat 4 mg (ROW) | 0 | 4 | 0 |
| other | Tympanic Membrane Perforation | Ear and labyrinth disorders | Part 1: Venglustat 8 mg (ROW) | 0 | 5 | 0 |
| other | Tympanic Membrane Perforation | Ear and labyrinth disorders | Part 1: Venglustat 15 mg (ROW) | 0 | 4 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02906020/events